Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01535209 : Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patients with surgically removed histologically proven metastatic cancer

- Subtotal or total resection of single brain metastasis

- Presence of single brain metastasis in MRI

- Karnofsky Performance Status ? 70

- Life expectancy > 6 months (minimal extracranial disease or availability of effective
oncology treatment)

- No previous history of cranial irradiation

- Availability of MRI

- Starting radiotherapy within six weeks after neurosurgery

- Negative pregnancy test for woman

- Written informed consent

Exclusion Criteria:

- Dementia and central nervous system diseases leading to higher risk of radiation
toxicity

- Contraindications for MRI and/or no patient's tolerance and acceptance of cranial MRI

- Altered level of consciousness

- Histologically proven metastatic small cell lung cancer
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01535209      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740